ACUTE MYELOID LEUKEMIA (AML)
Clinical trials for ACUTE MYELOID LEUKEMIA (AML) explained in plain language.
Never miss a new study
Get alerted when new ACUTE MYELOID LEUKEMIA (AML) trials appear
Sign up with your email to follow new studies for ACUTE MYELOID LEUKEMIA (AML), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New Triple-Drug attack shows promise in AML battle
Disease control Not yet recruitingThis study tests a new combination of three drugs (venetoclax, azacitidine, and mitoxantrone liposome) against the standard two-drug therapy for adults newly diagnosed with acute myeloid leukemia (AML). About 204 participants aged 18-65 will be randomly assigned to one of the two…
Matched conditions: ACUTE MYELOID LEUKEMIA (AML)
Phase: PHASE3 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated May 17, 2026 01:03 UTC
-
New transplant recipe aims to cut Graft-Versus-Host disease in blood cancer patients
Disease control Not yet recruitingThis early-phase study tests a new combination of chemotherapy drugs (thiotepa, busulfan, fludarabine) with a lower dose of post-transplant cyclophosphamide for stem cell transplants in people with certain blood cancers like leukemia and myelodysplastic syndrome. The goal is to s…
Matched conditions: ACUTE MYELOID LEUKEMIA (AML)
Phase: PHASE1 • Sponsor: Sawa Ito, MD • Aim: Disease control
Last updated May 17, 2026 00:51 UTC
-
New oral drug combo aims to tame tough leukemia
Disease control Not yet recruitingThis early-stage study tests an oral form of cladribine combined with two other drugs (low-dose cytarabine and venetoclax) in 58 adults with acute myeloid leukemia (AML). Part 1 finds the safest dose; Part 2 checks if that dose helps control the disease. The goal is to manage AML…
Matched conditions: ACUTE MYELOID LEUKEMIA (AML)
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 17, 2026 00:49 UTC
-
New blood test may guide smarter AML treatment choices
Disease control Not yet recruitingThis study tests a new blood test (5hmC) to see how well it tracks leftover cancer cells in people with acute myeloid leukemia (AML). About 112 adults with newly diagnosed AML will get either a milder drug or standard strong chemo, and the test will help doctors decide next steps…
Matched conditions: ACUTE MYELOID LEUKEMIA (AML)
Phase: PHASE2 • Sponsor: The Methodist Hospital Research Institute • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
Promising Three-Drug cocktail targets tough leukemia
Disease control Not yet recruitingThis study tests a new combination of three drugs (aclarubicin, azacitidine, and venetoclax) for people with acute myeloid leukemia (AML), including those newly diagnosed or whose cancer has returned. The goal is to find the safest dose and see if the combo helps control the dise…
Matched conditions: ACUTE MYELOID LEUKEMIA (AML)
Phase: PHASE1, PHASE2 • Sponsor: Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated May 14, 2026 12:06 UTC
-
Engineered immune cells take on tough leukemia in kids
Disease control Not yet recruitingThis early-phase study tests a personalized cell therapy called CART123, either alone or with the drug ruxolitinib, in children and young adults (up to age 29) whose acute myeloid leukemia (AML) has returned or not responded to standard treatments. The goal is to find a safe dose…
Matched conditions: ACUTE MYELOID LEUKEMIA (AML)
Phase: PHASE1 • Sponsor: Stephan Grupp MD PhD • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
New hope for tough leukemia: Three-Drug combo targets relapsed AML
Disease control Not yet recruitingThis study tests a combination of three drugs (cladribine, low-dose cytarabine, and venetoclax) in 24 adults with acute myeloid leukemia (AML) that has come back or not responded to prior treatment, especially after a venetoclax-based regimen. The goal is to see if this combo can…
Matched conditions: ACUTE MYELOID LEUKEMIA (AML)
Phase: PHASE2 • Sponsor: University of Rochester • Aim: Disease control
Last updated May 13, 2026 16:02 UTC
-
New hope for leukemia patients who failed standard therapy
Disease control Not yet recruitingThis study tests a new combination of three drugs (lisafotoclax, decitabine, and homoharringtonine) in 35 adults with acute myeloid leukemia (AML) whose cancer did not respond to or could not tolerate a common first treatment. The goal is to see if this new mix can shrink or elim…
Matched conditions: ACUTE MYELOID LEUKEMIA (AML)
Phase: PHASE2 • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated May 13, 2026 15:59 UTC
-
New hope for older AML patients: drug combo aims for remission without harsh chemo
Disease control Not yet recruitingThis study tests a combination of three drugs (venetoclax, homoharringtonine, and azacitidine) plus a growth factor in 61 older or frail adults with newly diagnosed acute myeloid leukemia (AML) who cannot tolerate standard intensive chemotherapy. The goal is to see if this treatm…
Matched conditions: ACUTE MYELOID LEUKEMIA (AML)
Phase: PHASE2 • Sponsor: First People's Hospital of Hangzhou • Aim: Disease control
Last updated May 11, 2026 20:47 UTC
-
New triple therapy aims to boost remission in elderly AML patients
Disease control Not yet recruitingThis phase 3 trial tests whether adding homoharringtonine to the standard two-drug regimen (venetoclax and azacitidine) improves remission rates in adults aged 60-75 with newly diagnosed acute myeloid leukemia (AML). About 308 participants will be randomly assigned to receive eit…
Matched conditions: ACUTE MYELOID LEUKEMIA (AML)
Phase: PHASE3 • Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated May 06, 2026 16:02 UTC
-
Can patients safely stop Anti-Rejection drugs sooner after transplant?
Disease control Not yet recruitingThis study tests whether patients who receive a stem cell transplant for blood cancers can safely stop taking the immune-suppressing drug tacrolimus earlier than usual. The goal is to reduce side effects while still preventing graft-versus-host disease (GVHD), a common complicati…
Matched conditions: ACUTE MYELOID LEUKEMIA (AML)
Phase: PHASE1 • Sponsor: Stanford University • Aim: Disease control
Last updated May 05, 2026 11:56 UTC
-
Massive data pool aims to crack childhood Leukemia's secrets
Knowledge-focused Not yet recruitingThis study gathers medical and genetic information from 2000 children with acute myeloid leukemia (AML) into one large database. The goal is to find hidden patterns that predict which children are at high risk of relapse. By combining data from many hospitals, researchers hope to…
Matched conditions: ACUTE MYELOID LEUKEMIA (AML)
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated May 13, 2026 16:00 UTC